$Sarepta疗法(SRPT)$ Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
| 发布于: | iPhone | 转发：0 | 回复：0 | 喜欢：0 |
$Sarepta疗法(SRPT)$ Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45